StockNews.AI

M&A

Merger or acquisition will directly impact the share value. Acquiring company shares may suffer while the target company shares would rise.
Typical direction
Depends
Signal relevance
High
Event signals
1 min delayed

Recent public signals classified as M&A, with first-party permanent pages for source and price-impact review.

AMGNOct 24, 20260.00% since signal

Amgen's IMDELLTRA combo yields 58% survival benefit in ES-SCLC

Amgen announced interim Phase 3 DeLLphi-305 results showing IMDELLTRA with durvalumab delivering a 58% reduction in death risk (HR 0.42). OS rose to 21.1 months, with about 80% alive at one year versus 53% on durvalumab alone; PFS HR 0.34 and ORR 26.4% versus 4.1%. Published in NEJM and presented at ESMO 2026, the data could drive regulatory interest and expand Amgen's oncology franchise.

View signal analysis
CRHOct 23, 2026-1.78% since signal

CRH closes $8.5B Arcosa deal, expanding US aggregates footprint

CRH has closed its $8.5 billion acquisition of Arcosa, expanding its aggregates-led platform in the United States. Arcosa adds scale in US aggregates and critical infrastructure products, reinforcing CRH’s geographic diversification and potential for logistics and port-related synergies, with integration driving longer-term margin and growth benefits.

View signal analysis
IPMOct 22, 2026+2.65% since signal

IPM to expand managed services through AdTech acquisition for up to $2.7 million

IPM announced a definitive agreement to buy AdTech's IT, telecom, and managed services unit for up to $2.7 million, via a two-stage closing to JVCo. The acquisition expands IPM's platform and should drive incremental capabilities, accelerating growth in enterprise cybersecurity and cloud services; however, timing and financial impact remain uncertain pending customary adjustments and closing conditions.

View signal analysis